A recent Glaxosmithlline Intellectual Property (No 4) Ltd. and Ideaya Biosciences Inc. patent describes the development of thiadiazolyl derivatives acting as DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.